"The Evaluation of Stimulant Withdrawal"

Withdrawn before enrolling · Phase 2

Conditions studied: Anxiety, Relapse, Substance Addiction

In brief

The purpose of this research study is to determine whether Carvedilol, an FDA approved beta blocker, when administered for an 8-week period to veterans currently undergoing treatment for methamphetamine dependence (1) improves their ability to stay in treatment longer, (2)eases the aversive symptoms that accompany stimulant withdrawal, and (3) increases the time they remain abstinent from methamphetamine.

Key facts

Study ID
NCT00442923
Run by
Aaron J. Janowsky
People needed
0
Starts
2007-07-01
Expected to finish
2011-06-30
Last updated by the study team
2019-01-31

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.